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ABSTRACT 
Aim: To assess the comparative effects of glucose-lowering drugs (GLDs) on diabetic 
retinopathy (DR) risk in patients with type 2 diabetes mellitus (T2DM).  
Methods: We systematically searched Cochrane Central Register of Controlled Trials, 
PUBMED, and EMBASE from each database’s inception to January 17, 2017 to identify 
randomized controlled trials (RCTs) that reported DR events among the T2DM patients 
receiving any GLD. Random-effects pairwise and network meta-analyses were 
performed to calculate the odds ratios (ORs) with 95% confidence intervals (CIs).  
Results: A total of 37 independent RCTs with 1,806 DR events among 100,928 patients 
with T2DM were included. The mean duration of diabetes was 8.7 years and mean 
baseline HbA1c was 8.2% (SD, 0.5%). Our network meta-analysis found that DPP-4i 
(OR, 1.20; 95% CI, 0.87 to1.65), GLP-1RA (OR, 1.19; 95% CI, 0.94 to1.52), and SGLT2 
inhibitors (OR, 0.79; 95% CI, 0.49 to 1.28) were not associated with a higher risk of DR 
than placebo; however, a significantly increased risk of DR was associated with DPP-4i 
in the pairwise meta-analysis (OR, 1.27; 95% CI, 1.05 to 1.53). Sulfonylureas, on the 
other hand, were associated with a significantly increased risk of DR compared to 
placebo (OR, 1.67; 95% CI, 1.01 to 2.76).  
Conclusions: Current evidence indicates that the association between DPP-4i, GLP-
1RA, or SGLT2 inhibitors and risk of DR remains uncertain in patients with T2DM. Some 
evidence suggests that sulfonylureas may be associated with increased risk of DR. 
However, given that DR events were not systematically assessed, these effects should 
be explored further in large-scale, well-designed studies.   
KEYWORDS 
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1 INTRODUCTION 
Diabetic retinopathy (DR) is the most common microvascular complication in patients 
with diabetes mellitus (DM) and the most frequent cause of blindness in adults 1-3. 
Studies demonstrate that intensive glycaemic control reduces the risk of long-term 
complications such as retinopathy, neuropathy, and nephropathy 4-6. Improving 
glycaemic control also reduces DR progression 7. However, a recent clinical trial of 
semaglutide (SUSTAIN - 6) 8 showed an increased risk of developing DR and 
complications of DR (defined as the need for retinal photocoagulation or treatment with 
intravitreal agents, vitreous hemorrhage, or onset of blindness) among subjects treated 
with semaglutide compared to subjects on placebo. In addition, some observational 
studies found that use of thiazolidinediones was associated with an increased risk of 
diabetic macular edema (DME) 9, 10. In contrast, a pre-clinical study showed that control 
of hyperglycaemia with ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) 
inhibitor, slowed the progression of retinopathy, nephropathy, and neuropathy 11. 
The effect of GLDs on the risk of DR remains uncertain. We therefore performed a 
meta-analysis of all available randomized controlled trials (RCTs) to test the effect of 
each class of GLDs (including dipeptidyl peptidase 4 inhibitors (DPP-4i), glucagon-like 
peptide-1 receptor agonists (GLP-1RA), SGLT2 inhibitors, glinides, α-glucosidase 
inhibitors, thiazolidinediones, sulfonylureas, metformin, insulin) on DR risk in patients 
with T2DM. Additionally, to distinguish the potential risk for developing DR among 
different classes of GLDs, we carried out this meta-analysis to evaluate the comparative 
safety of different classes of GLDs on risk of DR in these populations.  
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2 METHODS 
This network meta-analysis was conducted according to the PRISMA extension 
statement for the reporting of systematic reviews incorporating network meta-analyses 
of health care interventions12 and registered with PROSPERO (number CRD 
42017057945).  
2.1 Search strategy and study selection 
We comprehensively searched PubMed, Embase, Cochrane Central Register of 
Controlled Trials (CENTRAL), and Clinicaltrials.gov from inception to January 17, 2017 
to identify eligible RCTs. A detailed search strategy that included electronic databases 
and key terms is presented in Appendix 1. There were no restrictions regarding the 
language, date, or publication. In addition, we also identified other potential trials by 
manually searching the reference lists of included trials and relevant meta-analyses.  
Two reviewers (YZ and GL) independently selected the trials based on the following 
inclusion criteria: 1) RCTs that compared one or more GLDs with placebo, no treatment, 
or active treatments (including DPP-4i, GLP-1RA, SGLT2 inhibitors, glinides, α-
glucosidase inhibitors, thiazolidinediones, sulfonylureas, metformin, and insulin). When 
background therapy was specified, we required the background therapy to be identical 
between the intervention and control groups; 2) trial durations ≥ 24 weeks; and 3) trials 
reporting safety outcomes of DR (DR events include DR, macular edema, vitreous 
hemorrhage, onset of diabetes-related blindness, and the need for treatment with an 
intravitreal agent or retinal photocoagulation). Authors were contacted for further 
information if necessary. Data from the large trials (EMPA-REG OUTCOME 13, 
LEADERS 14, SUSTAIN-6 8) showed that the incidence of DR ranged from 3 to 14.9 
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cases/1000 person-years. In studies with a population >1000 patients and no reported 
DR events, we assumed that DR events were underreported. In these cases, we 
contacted study authors to inquire about DR events. Six of 20 authors contacted 
responded back; five provided additional data, and one clarified data.   
2.2 Data extraction and quality assessment  
Two reviewers (YZ and GL) independently extracted data from original trial reports 
using a standardized form. Data extracted included study characteristics (first author, 
publication year, NCT number, and duration of follow-up) and characteristics of patients 
(inclusion criteria, background treatments, mean age, proportion of men, duration of 
T2DM, baseline HbA1c%, and body mass index [BMI]), any GLD, comparators, and the 
incidence of DR). If multiple reports from the same population were retrieved, only the 
most complete and/or most recently reported data were used. If DR events were not 
reported in the manuscripts, we extracted the data from the “Serious Adverse Events” 
section on ClinicalTrials.gov. When both the publication and the clinicalTrials.gov of the 
same trial reported DR event, but data were not consistent, we contacted the authors 
for verification. 
Study quality was assessed by two reviewers using the Cochrane risk of bias tool as 
described in the Cochrane Collaboration Handbook 15. In cases of disagreement, a third 
reviewer (TW) was consulted to reach a consensus. We assessed the risk of bias based 
on the following domains: random sequence generation (selection bias), allocation 
concealment (selection bias), blinding (performance bias and detection bias), 
incomplete outcome data (attrition bias), and selective reporting (reporting bias). We 
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generated the risk of bias graphs with the Review Manager 5.3 software, with each 
domain judged as low risk, high risk, or unclear risk. 
2.3 Statistical analysis   
Direct meta-analysis was carried out using Mantel-Haenszel’s method with random 
effects models to calculate the odds ratio (ORs) and 95% confidence intervals (CIs) for 
direct comparisons between therapeutic regimens. Statistical heterogeneity was 
assessed using the I² statistic, with I2 of < 25%, ≥ 25 and < 75% , and ≥ 75% indicating 
low, medium, and high heterogeneity, respectively 16. For the comparisons including 
more than ten trials, publication bias was evaluated with funnel-plot symmetry and using 
the Egger regression. A sensitivity analysis using the person-years was performed to 
test the robustness of the results. 
For indirect and mixed comparisons, a network meta-analysis with a random-effects 
model using the “mvmeta” command and programmed STATA routines was used to 
calculate the ORs and 95% CIs between different interventions 17, 18. For zero-event 
RCTs, a 0.5 zero-cell correction was applied before meta-analysis 19. The relative 
ranking of GLDs on DR events was assessed by using their surface under the 
cumulative ranking curve (SUCRA), which represents their likelihood of being ranked 
safest. In this study, larger SUCRA probabilities indicate lower risk of DR events 20. The 
heterogeneity variance (tau) estimated by a restricted maximum likelihood method was 
employed to investigate between-study heterogeneity in the network meta-analysis 21.To 
check for the presence of inconsistency, a loop inconsistency–specific approach was 
introduced to evaluate the difference between direct and indirect estimates for a specific 
comparison 22.To check the assumption of consistency in the entire network, a design-
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by-treatment interaction model using the χ2 test was used 23. Finally, a comparison-
adjusted funnel plot was used to assess small study effects within a network of 
interventions 24. 
 
We performed a regression analysis to examine the relationship between trial 
characteristics and effect size by using the following factors: duration of diabetes, 
difference in glycaemic control change between groups, the absolute glycaemic control 
achieved in the experimental treatment group, and baseline systolic blood pressure. All 
meta-analyses were performed with STATA (Version 14; Stata Corp., College Station, 
TX) and SAS version 9.4 (SAS Institute, Cary, NC). A two-tailed P < 0.05 was 
considered statistically significant. 
3 RESULTS 
3.1 Study selection and Study characteristics 
Figure 1 shows the process of identifying eligible trials. We retrieved 11,428 studies 
through our electronic search and selected 1,692 potential trials. Eight months after our 
formal search, the results of the Exenatide Study of Cardiovascular Event Lowering 
(EXSCEL) were published in September 2017 57. We incorporated data from this large 
trial, and our final analysis included 36 manuscripts involving 37 trials 13, 14, 25-57 (Figure 
1). These included 34 two-group trials, 2 three-group trials 45, 47, and 1 four-group trial 56. 
The available direct comparisons and network of trials are shown in Figure 2.    
We summarize the study characteristics in Table 1 and Appendix 2. A total of 100,928 
patients with T2DM from 37 independent trials were randomly assigned to a GLD or 
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placebo. A total of 1,806 DR events were reported. Mean sample size was 2,728 
(range: 257 - 16,492), and the mean duration of follow-up ranged between 0.5-5.5 years 
(median, 1.5, interquartile range: 0.8-3.0). Participants were generally middle-aged 
(mean age: 58.3 years), with a mean diabetes duration of 8.7 years (interquartile range, 
6.2-11.4 years), and a mean baseline HbA1c level is 8.2% (SD, 0.5%). Mean baseline 
and end-of-study HbA1c% values are presented in Appendix 3.   
The risk of bias for the 37 RCTs is summarized as follows (Appendix 4): A total of 19 
RCTs reported adequate random sequence generation, and 23 RCTs reported 
adequate allocation concealment. Masking conditions were high in 6 RCTs, and 3 RCTs 
were judged as high risk for incomplete outcome data due to high loss to follow-up 
(24.0%, 34.4%, and 44.8%, respectively). Only two trials that predefined and 
adjudicated DR events had a low risk of other bias 8, 14.  
3.2 Pairwise meta-analysis 
Results of pairwise meta-analysis are presented in Appendix 5. DPP-4i were 
associated with a significantly increased risk of DR events as compared with placebo 
(OR, 1.27; 95% CI, 1.05 to 1.53) (Table 2). However, there were no significant 
differences found with GLP-1RA and SGLT2 inhibitors compared with placebo (OR, 
1.15; 95% CI, 0.93 to 1.43) and (OR, 0.78; 95% CI, 0.54 to 1.12), respectively (Table 
2). No statistically significant difference was observed in other head-to-head 
comparisons; effect estimates are imprecise due to the low number of events (including 
0 events in some trials). Overall, there was no evidence of significant heterogeneity 
observed, with one exception found between SGLT2 inhibitors and sulfonylureas (I2 = 
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69.1%). A sensitivity analysis using the numbers of person-years indicated all results 
were consistent (Appendix 6). There was no evidence of publication bias in the 
comparison of GLP-1RA and placebo, based on Egger’s test (P = 0.67), Begg’s test (P 
= 0.63) and visual inspection of the funnel plot (Appendix 7). 
3.3 Network meta-analysis 
In the network meta-analysis (Appendix 8), sulfonylureas were associated with a 
significantly increased risk of DR as compared with both placebo (OR, 1.67; 95% CI, 
1.01 to 2.76) and SGLT2 inhibitors (OR, 2.11; 95% CI, 1.07 to 4.17) (Table 2). There 
was no significant difference between DPP-4i (OR, 1.20; 95% CI, 0.87 to 1.65) or GLP-
1RA (OR, 1.19; 95% CI, 0.94 to 1.52) and placebo. Consistent with the results from 
pairwise meta-analysis, the risk of DR in SGLT2 inhibitors was similar to placebo (OR, 
0.79; 95% CI, 0.49 to 1.28). We generated hierarchies of treatment effects based on the 
SUCRA probabilities (Appendix 9). SGLT2 inhibitors were associated with the lowest 
probability for DR complications (SUCRA, 90.6%), followed by GLP-1RA (SUCRA, 
59.6%), DPP-4i (SUCRA, 58.8%), insulin (SUCRA, 55.4%), thiazolidinediones (SUCRA, 
41.9%), glinides (SUCRA, 36.3%), metformin (SUCRA, 33.7%), sulfonylureas (SUCRA, 
30.9%), and α-glucosidase inhibitors (SUCRA, 12.9%). There was low between-study 
heterogeneity (tau ≈ 0.18), no inconsistency between direct and indirect estimates (all 
95%CIs across zero) (Appendix 10), and no global inconsistency within any network (P 
= 0.80). In addition, the comparison-adjusted funnel plot indicated the absence of small-
study effects (Appendix 11).  
3.4 Regression analysis 
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In the multivariate regression of 11 trials (studies with missing variables were excluded 
from the multivariate regression), none of the pre-specified factors were found to be 
significant (Appendix 12). In the univariate regression of 22 trials, the risk of DR was 
associated with difference in HbA1c% change between groups (P = 0.04) (Figure 3).    
4 DISCUSSION 
Our study is the first network meta-analysis to address the safety of GLDs on DR 
events. We included 37 RCTs that reported 1,806 events among 100,928 patients with 
T2DM. In the network meta-analysis based on the direct and indirect evidence, we 
found that the risks of DR events in both DPP-4i and GLP-1RA were similar to placebo. 
However, in the pairwise meta-analysis, there was a significantly increased risk of DR 
associated with DPP-4i alone. There was also no significant association found between 
SGLT2 inhibitors and the risk of DR. In contrast, sulfonylureas were associated with a 
significantly increased risk of DR compared to placebo and SGLT2 inhibitors. Our 
univariate regression showed the difference in HbA1c% change between groups might 
be associated with DR risk (that is the greater reduction in HbA1c%, the lower the risk 
of DR). This finding is consistent with the current evidence 7, 58 and confirms the 
importance of achieving good glycaemic control to reduce the risk of DR. However, 
none of these pre-specified factors were found to significant in the multivariate 
regression. This might be due in large part, to the limited number of trials included in our 
meta-analysis. 
In contrast to the results from SUSTAIN - 6 8 and TECOS 25, the results from our 
network meta-analysis found no significant increase in the risk of DR in patients taking 
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DPP-4i or GLP-1RA, although an increased risk of DR associated with DPP-4i was 
detected in the pairwise meta-analysis, which was largely driven by TECOS 25. Recent 
evidence about the effects of incretin therapies on the microcirculation is scarce. 
Preclinical data demonstrated beneficial pleiotropic effects of incretin therapies in DR, 
independent of the glucose-lowering effect by reducing blood–retinal barrier breakdown, 
inflammation, and neuronal cell death 59-62. Topical administration of DPP-4i was shown 
to prevent neurodegeneration and vascular leakage in db/db mice by enhancing GLP-
163. The results in patients with T2DM remains inconsistent. In two small clinical studies, 
DPP-4i (saxagliptin and vildagliptin) were found to reduce retinal capillary blood blow 
and improve vasodilation 64, 65. In contrast, some GLP-1RA (liraglutide and exenatide) 
and DPP-4i (sitagliptin) had no effect on capillary perfusion in patients with T2DM 66. 
Although some experimental studies and small clinical trials indicated overall beneficial 
effects on the development of DR with GLP-1RA and DPP-4i, this is balanced by 
evidence of progressive worsening or a net neutrality of these agents on DR 67. 
Varadhan et al., found a progressive worsening of DR in patients treated for at least 6 
months with exenatide 68.The authors suggested that the worsening of DR might be due 
to the sudden and substantial reduction in HbA1c levels (initial HbA1c decrease of ≥ 
1.5%) caused by treatment 69 and subsequently found this effect to be transient and 
continued therapy with exenatide was associated with a reversal of this phenomenon 68. 
Several possible reasons to account for this observed phenomenon may lie in the short 
follow-up. Generally, five years is considered sufficient time to separate the incidence of 
DR between intervention and control groups 67. However the median duration of follow-
up of the included RCTs was 1.5 years (range: 0.5 - 5.5 years). Finally, lack of data on 
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the grading of DR at baseline and during the follow-up were reported in the clinical trials 
67. Further studies are required to clarify the risk of DR associated with DPP-4i or GLP-
1RA.  
Our meta-analysis found SGLT2 inhibitors were similar to placebo in the risk of DR. 
However, SGLT2 inhibitors were associated with the lowest risk among the GLDs in our 
network meta-analysis. Recently, a few studies explored the mechanism behind the 
beneficial effect of SGLT2 inhibitors on DR. One small trial involving 59 patients found 
that dapagliflozin, 10 mg/day administered for six weeks, significantly lowered retinal 
capillary flow compared to little change in the placebo group 70. In addition, dapagliflozin 
appeared to prevent changes to the structure of the retinal arterioles 70. The beneficial 
effects of SGLT2 inhibitors may be partly due to their blockade of renin–angiotensin 
system 71, 72, improved glycaemic control, and reduced blood pressure. However, these 
results are inconclusive and require further research to explore the risk of DR 
associated with SGLT2 inhibitors. 
Our network meta-analysis results also showed that sulfonylureas might be associated 
with a higher risk of DR compared to placebo, although the lower limit of the confidence 
interval is very close to the null. This result is inconsistent with direct evidence from the 
individual trials. The inconsistency might be partly due to lack of power to detect a 
statistical difference in the pairwise meta-analysis. In the UKPDS, each 1% reduction in 
HbA1c with intensive glucose therapies (sulfonylurea or insulin) was associated with a 
37% reduction in the risk of retinopathy 5. However, to our knowledge, no studies have 
assessed sulfonylurea monotherapy and the risk of retinopathy 73, 74. Thus, future 
studies are warranted to confirm our findings.   
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Two previous observational studies 9, 10 found an increased risk of macular edema 
associated with thiazolidinedione therapy, which had considerable limitations such as a 
lack of duration of individual patient exposure to thiazolidinediones. Our analysis did not 
observe an association between DR risk and thiazolidinediones, which is consistent with 
the ACCORD eye study 75, 76. Further studies are needed to examine the risk of DR for 
thiazolidinediones. 
Our meta-analysis of 37 randomized trials has several strengths. First, we used rigorous 
methodology to systematically identify and synthesize data. Second, in addition to 
published reports, our study also included 8 trials that were not published in peer-
reviewed journals, but were only identified from ClinicalTrials.gov. Third, we carefully 
checked the data in journal publications and clinicaltrials.gov for consistency, and 
contacted authors to ensure the data were accurate.  
Our meta-analysis has limitations as well. Firstly, none of the included trials were 
systematically designed to evaluate DR events. Only 5 trials clearly predefined a DR 
outcome 8, 13, 14, 25, 57 and the rest may have underreported DR events. Most data for DR 
endpoints come from adverse event reporting rather than the trial data itself. Such 
limitations decrease the validity of our meta-analysis. Second, due to the short-term 
follow up in the included clinical trials (median, 1.5 years), there may be insufficient 
follow up to fully assess the incidence of DR between intervention and control groups 67. 
Furthermore, since prior research suggested that a rapid reduction of HbA1c was 
associated with progression of microvascular disease followed by a resolution of 
symptoms, the current data included in our meta-analysis might overestimate this risk 
and underestimate the long-term overall benefits of HbA1c reduction. Third, lacking of 
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data on grading of DR at baseline and during the trials made it difficult to calculate the 
actual number of new adverse events. Fewer new events of DR would be reported if a 
study arm contained a disproportionate number of participants with previously treated 
retinopathy. In our meta-analysis only 5 trials with a predefined DR outcome 8, 13, 14, 25, 57, 
however, the methods used to detect and report DR were not clarified. Although it is 
more likely that only severe DR would be reported (i.e. less severe DR like mild or 
moderate non-proliferative DR were probably not reported), the unclear outcome 
definition from the included trials might weaken our internal validity. Finally, given the 
limited number of studies about metformin, α-glucosidase inhibitors, SGLT2 inhibitors, 
glinides, thiazolidinediones, and sulfonylureas included in our meta-analysis, the risk of 
DR for these classes of drugs remains uncertain.  
Our meta-analysis based on current evidence suggests that the DR risk associated with 
DPP-4i or GLP-1RA remains uncertain, while some evidence indicates that 
sulfonylureas may be associated with increased risk of DR. There was no significant 
difference between SGLT2 inhibitors and risk of DR. However, given that these events 
are may be underreported and DR was not systematically assessed as an endpoint, 
further data from large-scale, well-designed studies and real- world settings are 
warranted.  
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Table1 Baseline characteristics of included randomized controlled trials 
First author 
(year) 
Study ID   
ClinicalTrial.gov Name Patients Intervention Control 
Backgrou
nd 
treatment
s 
Follow -
up 
(years) 
Num
ber 
of 
pati
ents 
Age 
(yea
rs) 
Male 
(%) BMI 
HbA1
c (%) 
Duration of 
diabetes (years) 
Green 
(2015)25 NCT00790205 TECOS 
Patients with T2DM and established 
cardiovascular disease; excluded patients with 
a history of two or more episodes of severe 
hypoglycemia during the preceding 12 months 
or eGFR was ˂ 30 ml/min/1.73 m2. 
Sitagliptin Placebo 
one or two 
OADs 
(MET, 
pioglitazon
e, or SU) 
OR insulin 
± MET 
3.0 14671 65.5 
1034
7 
(70.7
) 
30.2 7.2 11.6 
White 
(2013)26 NCT00968708 
EXAMI
NE 
Patients with T2DM and an acute coronary 
syndrome within 15 to 90 days before 
randomization; excluded patients with unstable 
cardiac disorders (e.g., New York Heart 
Association class IV heart failure, refractory 
angina, uncontrolled arrhythmias, critical 
valvular heart disease, or severe uncontrolled 
hypertension), and dialysis within 14 days 
before screening. 
Alogliptin Placebo 
GLDs 
(with the 
exception 
of a DPP-
4 inhibitor 
or GLP-1 
analogue) 
1.5 5380 60.9 
3651 
(67.9
) 
29.5 8.0 9.2 
Owens 
(2011)27 NCT00602472 
 
Patients with T2DM and inadequate glycemic 
control with MET and SU; excluded patients 
with myocardial infarction, stroke or transient 
ischaemic attack within 6 months before 
enrolment, impaired hepatic function, renal 
failure or renal impairment. 
Linagliptin Placebo MET + SU 0.5 1055 58.1 
498 
(47.2
) 
28.3 8.1 
Up to 1 year 29 
(2.8) 
 1–5 years 249 
(23.9) 
> 5 years 762 
(73.3) 
Scirica 
(2013)28 NCT01107886 
SAVOR
-TIMI 
53 
Patients with T2DM and either a history of 
established cardiovascular disease or multiple 
risk factors for vascular disease; excluded 
patients with end-stage renal disease and were 
undergoing long-term dialysis, had undergone 
a renal transplantation, or had a serum 
creatinine level ˃ 6.0 mg/dl (530 µmol/L). 
Saxagliptin Placebo 
MET or 
SU or TZD 
or insulin 
2.1 16492 65.1 
1103
7 
(66.9
) 
31.1 8.0 10·3 
Barnett 
(2013)29 NCT00757588 
 
Patients with T2DM and inadequate glycemic 
control with insulin and MET; excluded patients 
with history of diabetic ketoacidosis or 
hyperosmolar nonketoticcoma, history of 
significant cardiovascular disease or 
hemoglobinopathy. 
Saxagliptin Placebo Insulin ± MET 1.0 455 57.2 
188 
(41.3
) 
32.3 8.7 11.9 
YKI-
JÄRVINEN 
(2013)30 
NCT00954447  
Patients with T2DM and inadequate glycemic 
control with basal insulin, alone or in 
combination with metformin and/or 
pioglitazone, for≥12 weeks; excluded patients 
with a myocardial infarction, stroke, or transient 
ischemic attack within 6 months before 
informed consent; impaired hepatic function. 
Linagliptin Placebo 
basal 
insulin ± 
MET ± 
pioglitazon
e 
1.0 1261 60.0 
658 
(52.2
) 
31.0 8.3 
Up to 1 year 26 
(2.1) 
 1–5 years 152 
(12.1) 
> 5 years 1057 
(83.8) 
Ferreira 
(2013)31 NCT00509262 
 
Patients with T2DM and had moderate to 
severe chronic renal insufficiency (eGFR＜50 
mL/min/1.73 m2); excluded patients with 
history of ketoacidosis, acute renal disease, 
Sitagliptin Glipizide None 1.1 422 64.2 
253 
(59.8
) 
26.8 7.8 10.4 
28  
renal transplant, liver disease, a recent (within 
3 months) cardiovascular event. 
Ahrén 
(2013)32 NCT00712673 
GETG
OAL-M 
Patients with T2DM inadequately controlled 
with metformin with a dose of at least 1.5 g/day 
for at least 3 months; history of unexplained 
pancreatitis, excluded patients with chronic 
pancreatitis, pancreatectomy, or inflammatory 
bowel disease, and history of metabolic 
acidosis. 
Lixisenatide Placebo MET 1.5 680 54.7 
293 
(43.1
) 
32.9 8.1 6.1 
Nauck 
(2016)33 NCT00849017 
HARM
ONY 2 
Patients with T2DM inadequately controlled 
with diet and exercise; excluded patients with 
recent cardiovascular and/or cerebrovascular 
disease. 
Albiglutide Placebo None 3.2 301 52.9 
166 
(55.1
) 
33.5 8.1 4.0 
Pfeffer 
(2015)34 NCT01147250 ELIXA 
Patients with T2DM and had an acute coronary 
event within 180 days before screening; 
excluded patients with percutaneous coronary 
intervention within the previous 15 days, 
coronary-artery bypass graft surgery for the 
qualifying event, planned coronary 
revascularization procedure within 90 days 
after screening, an eGFR of 
less than 30 ml/min/1.73 m2 . 
Lixisenatide Placebo 
MET or 
SU or 
Glinide or 
TZD or 
insulin as 
monothera
py OR 
insulin + 
OAD OR 
MET + SU 
OR Other 
GLDs 
2.1 6063 60.3 
4207 
(69.3
) 
30.2 7.7 9.3 
Marso 
(2016)14 NCT01179048 
LEADE
R 
Patients with T2DM and an age of 50 years or 
more with at least one cardiovascular 
coexisting condition or an age of 60 years or 
more with at least one cardiovascular risk 
factor; excluded patients with the occurrence of 
an acute coronary or cerebrovascular event 
within 14 days. 
Liraglutide Placebo 
one or 
more 
OADs or 
insulin or a 
combinatio
n of these 
agents 
3.8 9340 64.3 
6003 
(64.3
) 
32.5 8.7 12.9 
Marso 
(2016)8 NCT01720446 
SUSTAI
N-6 
Patients with T2DM and an age of 50 years or 
more with established cardiovascular disease 
(previous cardiovascular, cerebrovascular, or 
peripheral vascular disease), chronic heart 
failure (New York Heart Association class II or 
III), or chronic kidney disease of stage 3 or 
higher or an age of 60 years or more with at 
least one cardiovascular risk factor; excluded 
patients with a history of an acute coronary or 
cerebrovascular event within 90 days, planned 
revascularization of a coronary, carotid, or 
peripheral artery; or long term dialysis. 
Semaglutide Placebo 
a GLD or 
no more 
than two 
OADs, ± 
basal or 
premixed 
insulin 
2.1 3297 64.6 
2002 
(60.7
) 
32.8 8.7 13.9 
Kaku 
(2011)35 NCT00393718 
 
Patients with T2DM and inadequate glycemic 
control regardless of whether they were 
previously taking OAD. 
Liraglutide Glibenclamide ± OAD 1.0 400 58.3 
269 
(67.3
) 
24.8 9.3 8.3 
Wanner 
(2016)13 NCT01131676 
EMPA-
REG 
OUTC
OME 
Patients with T2DM and established 
cardiovascular disease and an eGFR of at 
least 30 ml/min/ 1.73 m2. 
Empagliflozin Placebo 
monothera
py or dual 
therapy of 
GLDs 
3.1 7020 63.1 
5016 
(71.5
) 
36.6 8.1 
≤1 years        
180(2.6%) 
>1 to 5 years 
1083(15.4%) 
>5 to 10 years 
1746(24.9%) 
>10 years        
4011(57.1%) 
Kovacs 
(2014)36 NCT01210001 
 Patients with T2DM inadequately controlled 
with diet and exercise and pioglitazone or Empagliflozin Placebo 
Pioglitazo
ne ± MET 0.5 498 54.5 
241 
(48.4 29.2 8.1 
≤1 year n=65 
(13.1); >1–5 years 
29  
pioglitazone plus metformin; excluded patients 
with estimated glomerular filtration rate of less 
than 30 mL/min per 1·73 m² (Modified Diet 
Renal Disease formula) 
) n=214 (43.0) ; >5–
10 years n=135 
(27.1); >10 years 
n=84 (16.9) 
Cefalu 
(2013)37 NCT00968812 
CANTA
TA-SU 
Patients with T2DM inadequately controlled 
with metformin; excluded patients with 
estimated glomerular filtration rate of less than 
55 mL/min per 1·73 m² 
Canagliflozin Glimepiride MET 2.0 1450 56.2 
756 
(52.1
) 
31.0 7.8 6.6 
Ridderstråle 
(2013)38 NCT01167881 
EMPA-
REG 
H2H-
SU trial 
Patients with T2DM inadequately controlled 
with metformin; excluded patients with 
estimated glomerular filtration rate of less than 
60 mL/min per 1·73 m² (Modified Diet Renal 
Disease formula) 
Empagliflozin Glimepiride MET 4.0 1545 55.9 
854 
(55.3
) 
30.1 7.9 
≤1 years 172 (11.1) 
>1 to 5 years 677 
(43.8) 
>5 to 10 years 425 
(27.5) 
>10 years 271 
(17.5) 
Pfützner 
(2011)39 NCT00327015 
 
Patients with T2DM and inadequate glycemic 
control; excluded patients with cardiovascular 
event within 6 months before study entry or 
New York Heart Association stage III/IV 
congestive heart failure and/or known left 
ventricular ejection fraction≤40%, significant 
renal, liver or psychiatric history 
Saxagliptin Metformin None 0.5 663 52.0 
332 
(50.1
) 
30.2 9.5 1.7 
Leiter 
(2014)40 NCT01098539 
 
Patients with T2DM, renal impairment(GFR: 15 
to 90 mL/min/1.73 m2) and inadequately 
controlled glycemia with diet and exercise 
and/or oral antihyperglycemic medications; 
excluded patients with recent clinically 
significant cardiovascular and/or 
cerebrovascular disease 
Albiglutide Sitagliptin 
MET, TZD, 
SU, or any 
combinatio
n of these 
OADs 
1.2 495 63.3 
266 
(53.7
) 
30.4 8.2 11.2 
Araki 
(2015)41 NCT01584232 
 
Patients with T2DM and inadequate glycemic 
control with sulphonylureas and/or biguanides; 
excluded patients with cardiovascular disease, 
liver disease, renal disease, poorly controlled 
hypertension, a history of chronic or acute 
pancreatitis, obvious clinical signs or 
symptoms of pancreatitis 
Dulaglutide Insulin glargine 
SU ± 
biguanides 0.5 361 56.8 
258 
(71.5
) 
26.0 8.0 8.8 
Diamant 
(2014)42 NCT00960661 
 
Patients with T2DM and inadequately 
controlled with insulin glargine and metformin 
with or without sulfonylurea 
Exenatide Insulin Lispro 
Insulin 
Glargine + 
MET 
0.6 627 59.5 
261 
(41.6
) 
32.5 8.3 11.5 
Weissman 
(2014)43 NCT00838916 
HARM
ONY 4 
Patients with T2DM inadequately controlled 
with metformin with or without sulfonylurea; 
excluded patients with recent significant 
cardiovascular (within 2 months) or 
cerebrovascular (within 1 month) events 
Albiglutide Insulin glargine MET ± SU 3.0 745 55.5 
418 
(56.1
) 
33.1 8.3 8.8 
Home 
(2009)_a44* NCT00379769 
RECO
RD 
Patients with T2DM inadequately controlled 
with metformin with or sulfonylurea; excluded 
patients with hospitalisation for a major 
cardiovascular event in the 3 months before 
the trial, planned cardiovascular intervention, 
and presence, history, or treatment for heart 
failure. 
Rosiglitazone Sulfonylurea MET 5.5 2222 57.1 
1185 
(53.4
) 
32.8 7.8 6.2 
Home 
(2009)_b44* NCT00379769 
RECO
RD 
Patients with T2DM inadequately controlled 
with metformin with or sulfonylurea; excluded 
patients with hospitalisation for a major 
cardiovascular event in the 3 months before 
the trial, planned cardiovascular intervention, 
and presence, history, or treatment for heart 
Rosiglitazone Metformin SU 5.5 2225 59.7 
1109 
(59.8
) 
30.2 8.0 7.9 
30  
failure. 
2016 45† NCT01709305  Patients with T2DM Acarbose 
Repaglini
de 
MET + 
sitagliptin 0.9 2195 NR NR NR NR NR 
Gliclazid
e 
Glimepiri
de 
Yang 
(2016)46 NCT01095666 
 
Patients with T2DM inadequately controlled 
with stable metformin monotherapy; excluded 
patients with any of the following 
cardiovascular/ vascular diseases within 6 
months of the enrolment visit: myocardial 
infarction, cardiac surgery or revascularization, 
unstable angina or congestive heart failure, 
transient ischemic attack or significant 
cerebrovascular disease 
Dapagliflozin Placebo MET 0.5 444 53.7 
241 
(54.3
) 
26.1 8.1 4.9 
201647 † NCT00839527  Patients with T2DM Albiglutide  
Pioglitaz
one 
MET + 
Glimepirid
e 
3.0 663 55.2 
353 
(53.2
) 
NR NR NR 
Placebo 
201548 † NCT01644500  Patients with T2DM Dulaglutide Glimepiride None 0.5 805 52.8 
426 
(53.9
) 
NR NR NR 
Seino 
(2016)49 NCT01572740 
 
Patients with T2DM inadequately controlled 
with stable insulin therapy in addition to diet 
and exercise for ≥12 weeks 
Liraglutide Placebo insulin 0.7 257 60.5 
144 
(56.0
) 
25.6 8.8 14.5 
201650 † NCT00849056  Patients with T2DM Albiglutide Placebo pioglitazone ± MET 3.0 301 55.0 
180 
(59.8
) 
NR NR NR 
Rosenstock 
(2014)51 NCT00713830 
GETG
OAL-S 
T2DM inadequately controlled with a 
sulfonylurea with or without metformin; 
excluded patients with history of myocardial 
infarction, stroke, or heart failure requiring 
hospitalization within the previous 6 months, 
uncontrolled/inadequately controlled 
hypertension, end-stage renal disease 
Lixisenatide Placebo SU ± MET 2.3 859 57.3 
434 
(50.5
) 
30.2 8.3 9.3 
Pinget 
(2013)52 NCT00763815 
GETG
OAL-P 
Patients with T2DM inadequately controlled 
with pioglitazone with or without metformin; 
excluded patients with history of unexplained 
pancreatitis, chronic pancreatitis, 
pancreatectomy, stomach/gastric surgery or 
inflammatory bowel disease, end-stage renal 
disease 
Lixisenatide Placebo Pioglitazone ± MET 2.5 484 55.8 
254 
(52.5
) 
33.9 8.1 8.1 
Seino 
(2011)53 NCT00395746 
 
Patients with T2DM inadequately controlled 
with diet therapy and one SU agent; excluded 
patients with proliferative retinopathy or 
maculopathy requiring acute treatment, 
impaired hepatic/renal function, serious heart 
disease, cancer, uncontrolled hypertension 
Liraglutide Placebo SU 1.0 264 59.7 
169 
(64.0
) 
24.9 8.8 10.3 
Rosenstock 
(2014)54 NCT00976391 
 
Patients with T2DM inadequately controlled 
with basal insulin, excluded patients with 
recent clinically significant cardiovascular or 
cerebrovascular disease 
Albiglutide Lispro insulin 
insulin 
glargine in 
combinatio
n with 
MET or 
TZD or 
both or 
neither 
1.2 566 55.6 
268 
(47.3
) 
NR(9
0.05
kg, 
BMI 
20-
45) 
8.5 11.0 
31  
Pratley 
(2010)55 NCT00700817 
 
Patients with T2DM inadequately controlled 
with metformin; excluded patients with 
impaired renal or hepatic function, clinically 
significant cardiovascular disease, recurrent 
major hypoglycaemia or hypoglycaemic 
unawareness 
Liraglutide Sitagliptin MET 0.5 658 55.3 
352 
(53.5
) 
32.8 8.4 6.2 
Ahrén 
(2014)56 NCT00838903 
HARM
ONY 3 
Patients with T2DM inadequately controlled 
with metformin; excluded patients with recent 
clinically significant cardiovascular and/or 
cerebrovascular disease (≤2 months before 
screening), resting systolic blood pressure ＞
160mmHg and/or diastolic blood pressure ＜
100 mmHg 
Albiglutide 
Sitaglipti
n 
MET 3.2 1012 54.5 
482 
(47.6
) 
32.6 8.1 6.0 
Glimepiri
de 
Placebo 
Holman 
(2017)57  NCT01144338 
EXSCE
L 
T2DM and a broad range of cardiovascular 
risk.Recruitment will be constrained such that 
approximately 30% will not have had a prior 
CV event and 70% will have had a prior CV 
event. 
Exenatide Placebo OADs ± insulin 3.2 
1475
2 62.0 
9149
(62.0
) 
31.7 8.0 12.0 
* Data from same study with different background therapy. 
† No publications were found, and last updated data in clinicaltrials.gov was extracted. 
Abbreviation: BMI, Body Mass Index; HbA1c, glycated haemoglobin; T2DM, type 2 diatbetes mellitus; MET, metformin; SU, sulphonylurea; TZD, thiazolidinedione; 
GLD, glucose-lowering drug; OAD, oral antihyperglycemic drug; ±, with or without; eGFR, estimated glomerular filtration rate 
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Table 2 Pairwise and network estimates of the effects of glucose-lowering drugs 
compared with placebo on risk of diabetic retinopathy 
Drug Direct drug 
comparisons/ 
participants (n/N) 
Odds ratio (95% CI) 
Pairwise meta-
analysis 
Network meta-analysis 
DPP-4i 443/39,717 1.27 (1.05, 1.53) 1.20 (0.87, 1.65) 
GLP-1RA 846/37,387 1.15 (0.93, 1.43) 1.19 (0.94, 1.52) 
SGLT2 inhibitors 124/7,962 0.78 (0.54, 1.12) 0.79 (0.49, 1.28) 
Sulfonylureas 16/408 2.37 (0.53, 10.59) 1.67 (1.01, 2.76) 
Thiazolidinediones 20/392 2.44 (0.70, 8.50) 1.50 (0.84, 2.67) 
Metformin ̶ ̶ 1.70 (0.80, 3.61) 
α-glucosidase 
inhibitors 
̶ ̶ 10.00 (0.38, 178.08) 
Glinides ̶ ̶ 3.37 (0.06, 178.08) 
Insulin ̶ ̶ 1.25 (0.73, 2.15) 
Abbreviations: n/N, number of events/number of patients; CI, confidence interval. 
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Figure Legends: 
Figure 1 Flow chart of study selection.(About eight months after our formal search, the 
results of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) were 
published in September 2017. We incorporated data from this large trial, and our final 
analysis included 36 studies) 
Figure 2 Network of available glucose-lowering drugs for risk of diabetic retinopathy. 
The size of the nodes corresponds to the number of trials including respective 
treatments. The directly compared treatments are linked with a line, the thickness of 
which corresponds to the number of trials that assessed this comparison. Numbers 
above and below the lines indicate studies and patients respectively. 
Figure 3 Univariate regression of the relation between HbA1C change and diabetic 
retinopathy risk. 
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Figure 1 
 
* One study reported by Home 2009 involves two RCTs with different background therapy. 
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Figure 2 
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Figure 3 
 
